Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from CanSino Biologics, Inc. Class H ( (HK:6185) ).
CanSino Biologics Inc. has received approval from China’s National Medical Products Administration for its 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13i). This vaccine, which uses advanced technology to enhance immunogenicity and safety, is the first in the company’s pneumococcal vaccine portfolio to gain such approval. The launch of PCV13i is expected to strengthen CanSino’s product portfolio and improve marketing efficiency, aligning with its existing high-end vaccine offerings.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, specializing in the development and production of vaccines. The company focuses on creating innovative vaccine solutions, with a market emphasis on high-end self-paid vaccines.
Average Trading Volume: 1,427,758
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.6B
For detailed information about 6185 stock, go to TipRanks’ Stock Analysis page.